Indian Journal of Medical and Paediatric Oncology, Table of Contents CC BY 4.0 · Indian J Med Paediatr Oncol DOI: 10.1055/s-0045-1808239 Letter to the Editor Final Overall Survival Results of PRIMA: The Niraparib Conundrum Akhil Santhosh 1 Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India › Author Affiliations Recommend Article Abstract Full Text References References 1 González-Martín A, Pothuri B, Vergote I. et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381 (25) 2391-2402 2 Monk BJ, Barretina-Ginesta MP, Pothuri B. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2024; 35 (11) 981-992 3 Lorusso D, Mouret-Reynier MA, Harter P. et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Int J Gynecol Cancer 2024; 34 (04) 550-558 4 Moore K, Colombo N, Scambia G. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379 (26) 2495-2505 5 Li N, Zhu J, Yin R. et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer. JAMA Oncol 2023; 9 (09) 1230-1237 6 Matulonis U, Herrstedt J, Oza A. et al. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6). Gynecol Oncol 2023; 176: S31-S32 7 Sghaier S, Corbaux P, Ray-Coquard I. et al. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. Future Oncol 2023; 19 (25) 1715-1727 8 Heitz F, Marth C, Henry S. et al. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. Int J Gynecol Cancer 2023; 33 (12) 1966-1969
